HXE

Arylcyclohexylamines produce sympathomimetic cardiovascular effects including tachycardia and hypertension. An acute MXE case documented ST-segment elevation. Individuals with uncontrolled hypertension, coronary artery disease, or arrhythmia face elevated cardiovascular risk.

alcohol, benzodiazepines, opioids, barbiturates, GHB

Combining HXE with CNS depressants produces additive sedation, respiratory depression, and loss of protective airway reflexes. The severity is compounded by HXE's intrinsic sedative properties at higher doses. This interaction pattern is well-established for the ketamine class.

NMDAR antagonists produce dose-dependent psychotomimetic effects including paranoia, thought disorganization, and reality testing impairment. Individuals with a personal or family history of schizophrenia, schizoaffective disorder, or other psychotic disorders are at elevated risk of acute psychotic decompensation.

Fatal MXE intoxication has been associated with rhabdomyolysis and hepatic failure. HXE, as a structural analog and metabolite of MXE, poses analogous risk. Individuals with pre-existing hepatic impairment may have reduced clearance and increased susceptibility to hepatotoxic outcomes.

Fatal MXE intoxication has been associated with acute renal failure secondary to rhabdomyolysis. HXE poses analogous risk as a structural analog. Individuals with pre-existing renal impairment should avoid use.

No reproductive toxicity data exist for HXE. NMDA receptor signaling plays critical roles in neurodevelopment, and NMDAR antagonist exposure during pregnancy is contraindicated as a precautionary measure. Animal studies with ketamine have demonstrated neurotoxicity in developing brains.

Chronic ketamine use causes progressive urothelial injury characterized by urinary frequency, urgency, dysuria, reduced bladder capacity, mucosal ulceration, and interstitial fibrosis. MXE was marketed as bladder-friendly but no data support this. HXE's bladder toxicity has not been studied but cannot be excluded. Individuals with pre-existing bladder conditions, interstitial cystitis, or history of ketamine-associated cystitis are at elevated risk.

MXE demonstrates appreciable serotonin transporter affinity and confirmed serotonergic activity in preclinical models. HXE, as the O-demethylation product of MXE, may retain SERT engagement. Concurrent use with monoamine oxidase inhibitors poses a theoretical serotonin syndrome risk. No published case of serotonin syndrome involving HXE or MXE with MAOIs exists, but the mechanism warrants precautionary avoidance.

amphetamine, methamphetamine, cocaine, MDMA

Fatal MXE-amphetamine co-intoxication in a 31-year-old male featured hyperthermia exceeding 39°C, rhabdomyolysis, hepatic failure, acute renal failure, and multi-organ dysfunction — at MXE blood levels within the typical intoxication range. This demonstrates that combining NMDAR antagonists with sympathomimetic stimulants can produce rapidly lethal synergistic toxicity.